| 146 | |
| Summary | Gut microbes (currently unknown members) affect Methotrexate's activity. |
| Gut | |
| Methotrexate (PubChem CID: 126941) | |
| unknown | |
| 33440172 | |
| affect activity | |
| Methotrexate, a dihydrofolate reductase inhibitor, is commonly used to treat rheumatoid arthritis. Methotrexate affects both mammalian and bacterial dihydrofolate metabolism. Consequently, the gut microbiota of treated patients differs from that of non-treated individuals. Surprisingly, responders and non-responders differ in their gut microbiome, suggesting that microbiota composition may influence drug efficacy. Fecal transplantation from responder patients to germ-free mice resulted in reduced immune activation after experimentally induced inflammation, compared to transplants from non-responders or controls. This fecal transplantation experiment supports the role of microbiota in mediating methotrexate’s effects. |
Browse Drug-Microbiome Relationship
Home